CCX 354

Drug Profile

CCX 354

Alternative Names: 2941266; CCX354; CCX354-C; GSK-2941266

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ChemoCentryx
  • Class Antirheumatics; Small molecules
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 17 Jun 2015 Clinical development for rheumatoid arthritis is ongoing
  • 14 Mar 2014 ChemoCentryx completes two phase I trials in Rheumatoid arthritis (in volunteers) in USA before March 2014
  • 03 Dec 2013 CCX 354 is no longer licensed to GSK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top